The Novartis-partnered p53 gene-targeting siRNA cut the rate of acute kidney injury in patients following cardiac surgery.

More biopharma news of note for Thursday.

A BMJ paper has shown that progress is being made on clinical trial transparency, although there is still a way to go.

PARP inhibitor Lynparza may be able to kill cancer cells that don’t have BRCA mutations—provided it’s paired with a helper compound.

Roche has joined partners Senseonics and TypeZero to develop a closed-loop system for insulin delivery.

Get Wednesday's shot of biopharma news of note.

University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.

The decision follows a review that foresaw bleak prospects for the program and little reason to invest in its development.

EnteroMedics will modify its obesity-treating neuromodulation system for Galvani Bioelectronics to use in preclinical research.